Ephedrine Sulfate

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Danger

H301 (71.4%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P270, P272, P280, P301+P316, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 147 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Regulation (EC) No 178/2002 (amended)

Status: Active Update: 17-07-2015 https://echa.europa.eu/registration-dossier/-/registered-dossier/11520

SYMPTOMS: Symptoms of exposure to this compound may include nervousness, headache, sweating, nausea and vomiting. Contact dermatitis may occur. Other symptoms include an increase in pulse rate and an increase in blood pressure. Exposure may cause irritation of the skin, eyes and respiratory tract, central nervous system effects, peripheral nervous system effects, loss of appetite, tremors and, in severe cases, convulsions, coma and death. Sleeplessness, restlessness and urinary retention may occur. This compound may cause excitation, insomnia, palpitation, tachycardia, precordial pain, cardiac arrhythmias, vertigo, dryness of the nose and throat, warmth, vesical sphincter spasm and urinary hesitation. It may also cause anxiety, extrasystoles, confusion and delirium. Other symptoms include chills, cyanosis, irritability, fever, suicidal behavior, mania, dilated pupils, blurred vision, opisthotonos, spasms, pulmonary edema, gasping respiration, respiratory failure and anuria. Exposure can lead to giddiness, thirst, difficulty in micturition, muscular weakness, hypertension and ventricular arrhythmias. Overexposure can cause paranoid psychoses, delusions and hallucinations. Mydriasis may occur.

EPHEDRINE SULFATE

beta-Adrenergic Agonist [EPC]; alpha-Adrenergic Agonist [EPC]; Adrenergic alpha-Agonists [MoA]; Increased Norepinephrine Activity [PE]; Adrenergic beta-Agonists [MoA]; Norepinephrine Releasing Agent [EPC]

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.

Drugs used to cause constriction of the blood vessels.

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.